State Street Corp Has $4.78 Million Stock Position in Codexis, Inc. (NASDAQ:CDXS)

State Street Corp raised its position in Codexis, Inc. (NASDAQ:CDXS) by 2.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,551,411 shares of the biotechnology company’s stock after buying an additional 41,480 shares during the period. State Street Corp’s holdings in Codexis were worth $4,778,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CDXS. abrdn plc raised its stake in shares of Codexis by 62.5% in the third quarter. abrdn plc now owns 800,410 shares of the biotechnology company’s stock valued at $2,465,000 after acquiring an additional 307,762 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Codexis by 23.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,103,442 shares of the biotechnology company’s stock valued at $3,399,000 after purchasing an additional 209,207 shares during the last quarter. AQR Capital Management LLC raised its position in Codexis by 82.4% in the 2nd quarter. AQR Capital Management LLC now owns 237,272 shares of the biotechnology company’s stock valued at $736,000 after purchasing an additional 107,205 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Codexis by 34.5% in the second quarter. Dimensional Fund Advisors LP now owns 340,762 shares of the biotechnology company’s stock worth $1,056,000 after purchasing an additional 87,457 shares in the last quarter. Finally, FMR LLC grew its holdings in shares of Codexis by 1.2% during the third quarter. FMR LLC now owns 4,497,090 shares of the biotechnology company’s stock worth $13,851,000 after purchasing an additional 51,822 shares during the last quarter. 78.54% of the stock is currently owned by institutional investors and hedge funds.

Codexis Stock Up 0.4 %

NASDAQ CDXS opened at $4.99 on Monday. The stock has a market capitalization of $406.08 million, a P/E ratio of -5.74 and a beta of 2.15. Codexis, Inc. has a 52 week low of $2.53 and a 52 week high of $6.08. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21. The stock has a fifty day moving average of $4.38 and a 200-day moving average of $3.54.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. The firm had revenue of $12.83 million during the quarter, compared to analyst estimates of $11.64 million. During the same quarter in the previous year, the business earned ($0.26) earnings per share. On average, equities research analysts forecast that Codexis, Inc. will post -0.77 EPS for the current year.

Analysts Set New Price Targets

CDXS has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 price target on shares of Codexis in a report on Friday, November 22nd. Benchmark reaffirmed a “hold” rating on shares of Codexis in a research note on Monday, November 4th.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.